**Supplemental Digital Content:**

Supplemental Digital Content 1.Distribution of inflammatory indicators and HALP scores in patients (n=626)

|  |  |
| --- | --- |
| **Characteristic** | **Patients (N=626)** |
| **HGB(g/L)** |  |
| Mean (±SD) | 119.00(±17.42) |
| Median (range) | 123.00(68.00-169.00 |
| **Albumin(g/L)** |  |
| Mean (±SD) | 42.39(±4.15) |
| Median (range) | 43.00(24.00-64.00) |
| **Lymphocyte(×109/L)** |  |
| Mean (±SD) | 1.72(±0.56) |
| Median (range) | 1.67(0.32-3.89) |
| **Blood****platelet****(×109/L)** |  |
| Mean (±SD) | 220.04(±66.76) |
| Median (range) | 211.50(66.00-588.00) |
| **HALP** |  |
| Mean (±SD) | 43.76(±22.44) |
| Median (range) | 41.16(5.73-185.60) |
| **Abbreviations:** HGB, Hemoglobin; HALP, hemoglobin, albumin, lymphocyte, and platelet. |

Supplemental Digital Content 2: Comparison of clinicopathological parameters between the high-HALP group and the low-HALP group (n=626)

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **low-HALP group****N=216** | **high-HALP group****N=410** | **P-value** |
| **Age(yrs.)** |  |  | 0.043 |
| <60 | 169 | 290 |
| ≥60 | 47 | 120 |
| **FIGO stage** |  |  |  |
| I | 129 | 307 | <0.001 |
| II | 25 | 32 | 0.001 |
| III | 62 | 71 | <0.001 |
| **Histotypes** |  |  | <0.001 |
| I | 132 | 314 |
| II | 84 | 96 |
| **Cervical stromal invasion** |  |  | 0.004 |
| Yes | 48 | 54 |
| No | 168 | 356 |
| **Myometrial invasion** |  |  | 0.203 |
| Yes | 75 | 122 |
| No | 141 | 288 |
| **LVSI** |  |  | 0.002 |
| Positive | 65 | 78 |
| negative | 151 | 332 |
| **LNM** |  |  | <0.001 |
| Yes | 166 | 369 |
| No | 50 | 41 |
| **Adjuvant treatment** |  |  | 0.004 |
| Yes | 146 | 229 |
| No | 70 | 181 |
| **Abbreviations:** FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphatic vessel space invasion; LN, lymph node; HALP, hemoglobin, albumin, lymphocyte, and platelet. |